Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Terrosa

- PMLiVE

Novo seeks to strengthen Tresiba label in US

Studies find insulin degludec advantage over insulin glargine

- PMLiVE

Pfizer gets FDA panel recommendation for biosimilar EPO

Product could be the first direct competitor to Epogen and Procrit in the US

- PMLiVE

MSD probed by UK for blocking Remicade biosimilars

Pharma giant’s discount scheme for infliximab labelled ‘anti-competitive’

- PMLiVE

Keytruda is first FDA-approved drug for molecular indication

Indicates a significant development in the shift towards personalised medicine

- PMLiVE

Merck says Afferent’s chronic cough drug clears mid-stage trial

MK-7264 reduces coughs per hour by 37%

Sanofi reception

Sanofi/Regeneron’s Sarilumab cleared by FDA on second attempt

IL-6 inhibitor to treat adult RA patients

- PMLiVE

Payback time nears as Sanofi gets CHMP backing for biosimilar Humalog

Panel recommends insulin Lispro Sanofi to treat diabetes

- PMLiVE

Merck takes on Roche with first-line bladder OK for Keytruda

FDA awards accelerated approval for mUC patients

- PMLiVE

Eli Lilly appoints senior VP for corporate affairs and communications

Leigh Ann Pusey joins from the American Insurance Association

- PMLiVE

Merck gains ground in lung cancer with first-line combo approval

Keytruda wins FDA backing for all first-line NSCLC patients

Sanofi targets patient literacy in clinical trials drive

Unveils new online resources for those in the US

Sanofi reception

Sanofi agrees €250m diabetes deal with AI firm Exscientia

The French pharma giant will pay royalties and contribute research funding

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links